COVID-19 UPDATE

BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

Analyst Coverage

Analyst Coverage

Analyst
Firm
Brandon Folkes
Cantor Fitzgerald
Oren Livnat
HC Wainwright & Co.
Tim Chiang
Northland Securities
David Amsellem
Piper Sandler
Scott Henry
ROTH Capital Partners
Gregg Gilbert
SunTrust Robinson Humphrey, Inc.
Tim Lugo
William Blair

BioDelivery Sciences International, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding BioDelivery Sciences International, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of BioDelivery Sciences International, Inc. or its management. BioDelivery Sciences International, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Investor Presentation

More information is coming soon.


Recent BDSI News

BioDelivery Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021 February 17, 2021

RALEIGH, N.C. , Feb. 17, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its fourth quarter and full ...

Read more
BioDelivery Sciences CFO Terry Coelho Promoted to Executive Vice President February 11, 2021

Brings Track Record of Success to Expanded Role RALEIGH, N.C. , Feb. 11, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, promoted its Chief Financial Officer, ...

Read more
BioDelivery Sciences to Present Three Scientific Posters Comparing BELBUCA® to Oxycodone at the 2021 North American Neuromodulation Society (NANS) Meeting January 15, 2021

Oral Presentation of Data from Phase I Safety Study & Secondary Respiratory Outcomes Comparing BELBUCA ® to Oxycodone on January 16 from 1:10pm – 2:10pm CT RALEIGH, N.C. , Jan. 15, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty ...

Read more

Upcoming Events

BDSI Fourth Quarter 2020 Financial Results Call and Webcast
 Mar 10, 2021 at 8:30 AM EST

Stay Connected

Stay up to date on the latest news

Get started now
February 12, 2021 /
Data provided by West LLC. Minimum 15 minutes delayed.